Post Essential Thrombocythaemia Myelofibrosis — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for post essential thrombocythaemia myelofibrosis. 5 active patents protecting 1 drugs from 1+ originators. First major cliff: 2026. Daily refresh.

1
Approved drugs
5
Active US patents
48/100
Avg vulnerability
—
Annual revenue covered

Originators in Post Essential Thrombocythaemia Myelofibrosis

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Bristol-Myers Squibb 5 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating post essential thrombocythaemia myelofibrosis. Each bar = one year. Y-axis scaled to peak year (1 patents).

1
26
1
28
1
31
1
32
1
39

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Inrebic
FEDRATINIB HYDROCHLORIDE
 Bristol-Myers Squibb 5 48 — 2026-12-16

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
8138199 Inrebic method of use 75 2028-06-30
11400092 Inrebic method of use 70 2039-09-24
10391094 Inrebic method of use 62 2032-06-04
7825246 Inrebic composition of matter 22 2026-12-16
7528143 Inrebic composition of matter 10 2031-11-16

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
7528143 Inrebic composition of matter 10 2031-11-16
7825246 Inrebic composition of matter 22 2026-12-16
10391094 Inrebic method of use 62 2032-06-04
11400092 Inrebic method of use 70 2039-09-24
8138199 Inrebic method of use 75 2028-06-30

Related